High impact
Nusinersen (Spinraza™)
BCBS Tennessee·Effective Dec 1, 2026
BlueCross BlueShield of Tennessee has issued a new medical policy for Nusinersen (Spinraza™) covering treatment of spinal muscular atrophy (SMA). The policy establishes comprehensive coverage criteria requiring prior authorization, genetic testing confirmation (≤3 SMN2 gene copies), neurologist prescription, baseline laboratory tests, and documented motor/respiratory function. The policy is NOT YET EFFECTIVE and must not be implemented until December 1, 2026.